Guildford, UK: MedPharm (www.medpharm.com), the leading topical and transdermal formulation development specialist today announced the formation of its new USA based subsidiary; MP Pharma Services Inc. Leading the initiation of the new laboratories, the company has announced the appointment of Jon Lenn as VP of US Operations.
MedPharm is delighted to announce the formation of its new USA based laboratories MP Pharma Services Inc. With a targeted operational date in Q1 2016, the services offered in the US will initially focus on topical and transdermal formulation performance testing. Among other services, the facility will provide access to MedPharm’s unique, validated in vitro models, complementing the UK based operation and offering a significant increase in capacity, as well as new services to the company’s clients. It is an important expansion for MedPharm with USA based business accounting for 50% of company revenues. The operation will be led by Jon Lenn who has been recruited as the first of a number of new appointments to join the new facility in RTP, North Carolina.
“MedPharm is already the leading company in this field and we continue to cement this reputation by adding new services and bringing in the latest know-how to the company. The expertise that Jon brings to the table is of incredible value as we expand the company into the US. As well as offering an increase in services and capacity to all of our partners, our clients in North and South America will now also benefit from having the opportunity for even closer contact with MedPharm.” commented Dr Andrew Muddle, CEO.
Jon brings with him an extensive and impressive portfolio of experience in topical and transdermal drug delivery. Jon has held senior positions in Stiefel and GSK, specialising in skin biology and topical and transdermal formulation development. During his career he has been instrumental in numerous successful NDA and ANDA regulatory submissions including EVOCLIN®, VERDESO®, OLUX-E®, EXTINA®, VELTIN®, SORILUX®, FABIOR®, & DUAC LD®.
Prof Brown CSO states; “We are all delighted to be able to bring Jon on board. He brings with him a vast wealth of experience from his time in industry and we are certain that our clients will benefit enormously from his input in their projects at MedPharm”
Follow us on LinkedIn
Back to News